Results 141 to 150 of about 32,062 (289)
Irish Haemophilia Society annual report 2013
, 2013 During 2013 the Society continued to work on behalf of its members with particular focus on development in many areas including, services to members, fundraising, educational grants and conference attendance.
Irish Haemophilia Society (IHS)
core
Haemophilia, EarlyView.ABSTRACT Introduction Individuals diagnosed with types 1/1C/2A/2M von Willebrand disease (VWD) typically undergo a desmopressin (DDAVP) challenge to assess therapeutic benefit. This involves measuring von Willebrand factor antigen (VWF:Ag), activity (VWF:Act; VWF:RCo/VWF:GPIbM/VWF:Ab), and coagulant factor VIII (FVIII:C) levels 0 (pre), 1, and 4‐h post‐
Michael Shu +7 more
wiley +1 more source
Haemophilia, EarlyView.ABSTRACT Introduction Accurate laboratory diagnosis is essential for the effective management of bleeding disorders. The World Federation of Hemophilia (WFH) International External Quality Assessment Scheme (IEQAS) provides an international platform for comparative evaluation of laboratory performance.
Silmara de Lima Montalvão +8 more
wiley +1 more source
Haemophilia, EarlyView.ABSTRACT Introduction Emicizumab is a bispecific antibody approved for prophylaxis in people with haemophilia A (PwHA). Aim To describe from the physician perspective the characteristics and treatment experiences of PwHA receiving emicizumab. Methods The Adelphi Real World Haemophilia Disease Specific Programme is a cross‐sectional, retrospective data ...
Michael Recht +7 more
wiley +1 more source
????? ??????? ?????? ???????? ???? ??? ???? ???????)???????????( ?? ?????? ????????
مجلة علوم ذي قار, 2019 This study aims to diagnosis some of the sickness cases by (Haemophilia) on some patients in three different healthy centers in al-Dewanya city . For such purpose , fifty cases of sickness by such disease are collected and laboratory test on them are ...
الاء محمد حسون +2 more
doaj
Haemophilia, EarlyView.ABSTRACT Background Evidence on the impact of emicizumab on joint health, particularly hypertrophic synovium (HS), remains limited. Objectives To evaluate changes in HS, using point‐of‐care ultrasound and clinical examination in People with Haemophilia (PwH) switching from replacement therapy to emicizumab.
Matteo Nicola Dario Di Minno +8 more
wiley +1 more source
Risk of Postpartum Hemorrhage in Women With Von Willebrand Disease: A Real‐World Data Analysis
Haemophilia, EarlyView.ABSTRACT Introduction Women with von Willebrand disease (VWD) are at increased risk for postpartum hemorrhage (PPH), but contemporary United States data on maternal outcomes and real‐world peripartum treatment patterns are limited. Aim To evaluate maternal outcomes associated with claims‐recorded VWD in a national claims cohort and describe exploratory
Mayank Patel +4 more
wiley +1 more source
Living With Factor VII Deficiency—A Mixed Methods Study
Haemophilia, EarlyView.ABSTRACT Background Factor VII deficiency (FVIID) is a rare autosomal recessive disorder, resulting in potentially unpredictable and life‐threatening bleeding. The prevalence of symptomatic patients is 1 in 300,000. Treatment is mostly given following bleeding, but those with the lowest levels may be offered prophylaxis.
Simon Fletcher +3 more
wiley +1 more source